RhumbLine Advisers’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-804
| Closed | -$13.4K | – | 4357 |
|
|
2024
Q2 | $13.4K | Sell |
804
-2,196
| -73% | -$36.5K | ﹤0.01% | 3936 |
|
|
2024
Q1 | $52.1K | Buy |
3,000
+234
| +8% | +$4.06K | ﹤0.01% | 3617 |
|
|
2023
Q4 | $43.3K | Sell |
2,766
-693
| -20% | -$10.8K | ﹤0.01% | 3660 |
|
|
2023
Q3 | $171K | Buy |
3,459
+682
| +25% | +$33.7K | ﹤0.01% | 3243 |
|
|
2023
Q2 | $217K | Buy |
2,777
+673
| +32% | +$52.6K | ﹤0.01% | 3201 |
|
|
2023
Q1 | $191K | Sell |
2,104
-53
| -2% | -$4.81K | ﹤0.01% | 2748 |
|
|
2022
Q4 | $254K | Buy |
2,157
+83
| +4% | +$9.77K | ﹤0.01% | 2727 |
|
|
2022
Q3 | $376K | Buy |
2,074
+186
| +10% | +$33.7K | ﹤0.01% | 2626 |
|
|
2022
Q2 | $169K | Buy |
1,888
+640
| +51% | +$57.3K | ﹤0.01% | 2971 |
|
|
2022
Q1 | $194K | Buy |
1,248
+44
| +4% | +$6.84K | ﹤0.01% | 2764 |
|
|
2021
Q4 | $358K | Sell |
1,204
-22
| -2% | -$6.54K | ﹤0.01% | 2646 |
|
|
2021
Q3 | $707K | Buy |
1,226
+57
| +5% | +$32.9K | ﹤0.01% | 2392 |
|
|
2021
Q2 | $531K | Sell |
1,169
-86
| -7% | -$39.1K | ﹤0.01% | 2538 |
|
|
2021
Q1 | $675K | Buy |
1,255
+390
| +45% | +$210K | ﹤0.01% | 2358 |
|
|
2020
Q4 | $765K | Buy |
865
+167
| +24% | +$148K | ﹤0.01% | 2261 |
|
|
2020
Q3 | $441K | Buy |
+698
| New | +$441K | ﹤0.01% | 2343 |
|